Enanta Pharma (ENTA) Misses Q3 EPS by 17c

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.67), $0.17 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $14.35 million versus the consensus estimate of $17.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Londian Wason New Energy Tech opens at $26, above IPO price of $22
• YETI Holdings, Inc. (YETI) call put ratio 19 calls to 1 put with a focus on September 55 calls into quarter results
• BTIG homebuilder survey shows July sales decline amid rate surge